It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
BH3-mimetics represent promising anti-cancer agents in tumors that rely on the anti-apoptotic function of B-Cell Lymphoma 2 (BCL2) proteins, particularly in leukemia and lymphoma cells primed for apoptosis. Mechanistically, BH3-mimetics may displace pro-apoptotic binding partners thus inducing BAX/BAK-mediated mitochondrial permeabilization followed by cytochrome c release, activation of the caspase cascade and apoptosis. Here, we describe a novel mode of caspase-independent cell death (CICD) induced by BH3-mimetics in a subset of diffuse large B-cell lymphoma (DLBCL) cells. Of note, rather than occurring via necroptosis, CICD induced immediately after mitochondrial permeabilization was associated with transcriptional reprogramming mediated by activation of c-Jun N-terminal Kinase (JNK) signaling and Activator Protein 1 (AP1). Thereby, CICD resulted in the JNK/AP1-mediated upregulation of inflammatory chemokines and increased migration of cytotoxic Natural Killer (NK) cells. Taken together, our study describes a novel mode of CICD triggered by BH3-mimetics that may alter the immune response towards dying cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Goethe University Frankfurt, Institute for Experimental Pediatric Hematology and Oncology, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721)
2 University of Leicester, The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, Leicester, UK (GRID:grid.9918.9) (ISNI:0000 0004 1936 8411)
3 Goethe University Frankfurt, Faculty of Medicine, Institute of Biochemistry I, Frankfurt am Main, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721)
4 Goethe University Frankfurt, Faculty of Medicine, Institute of Biochemistry I, Frankfurt am Main, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); a partnership between DKFZ and University Hospital Frankfurt, German Cancer Consortium (DKTK) partner site Frankfurt/Mainz, Frankfurt, Germany (GRID:grid.411088.4) (ISNI:0000 0004 0578 8220)
5 Goethe University Frankfurt, Institute for Experimental Pediatric Hematology and Oncology, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); a partnership between DKFZ and University Hospital Frankfurt, German Cancer Consortium (DKTK) partner site Frankfurt/Mainz, Frankfurt, Germany (GRID:grid.411088.4) (ISNI:0000 0004 0578 8220); Goethe-University Frankfurt, University Cancer Center Frankfurt (UCT), University Hospital Frankfurt, Frankfurt, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721)